---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000053"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:23:41.593097+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics cuts 25% workforce, targets 20% OPEX reduction

## Summary
- Workforce reduction of ~25% primarily in US early-stage research and gene therapy manufacturing.
- Estimated severance and benefit costs of ~$21M, substantially all cash expenditures.
- Annualized operating expenses expected to drop ~20% vs 2023 OPEX guidance.
- Plans to submit re-examination request for CHMP negative opinion on Translarna.
- Reduction substantially complete by January 15, 2024.

## SEC filing metadata
- accession: 0001070081-23-000053
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/0001070081-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/tmb-20230928x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000053
- JSON: https://secwatch.observer/filing/0001070081-23-000053.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000053.txt

## Key facts
- Restructurings & Charges
  PTC THERAPEUTICS, INC. announced a restructuring with charges of approximately $21.0 million affecting early-stage research and gene therapy manufacturing and associated selling, general and administrative functions in the United States (approximately 25%).
  - Type: restructuring
  - Charge: approximately $21.0 million
  - Affected area: early-stage research and gene therapy manufacturing and associated selling, general and administrative functions in the United States
  - Headcount: approximately 25%
  source text: On September 28, 2023, PTC Therapeutics, Inc. (the “Company”) announced further strategic prioritization following the continued review of its portfolio that the Company began in May 2023. In connection with the strategic prioritization, on September 28, 2023, the Company committed to a reduction in workforce of approximately 25%, which will primarily affect employees in the United States, including those employees involved in early-stage research and gene therapy manufacturing and associated selling, general and administrative functions. The Company plans to substantially complete the reduction in workforce by January 15, 2024. Affected employees will be offered separation benefits, including severance payments along with temporary healthcare coverage assistance and other benefits. The Company estimates that the employee severance and benefit costs along with required pre-termination associated payments and benefits will be approximately $21.0 million, substantially all of which are e
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/0001070081-23-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.